What progress have you made since your last update?

Please see below!

What are your next steps?

Please see below!

Is there anything others could help you with?

Please see below!

Please see below for the update.

Update: Our manuscript on considerations on how best to introduce the two new drugs for gonorrhea, gepotidacin and zoliflodacin, was published (https://pmc.ncbi.nlm.nih.gov/articles/PMC12236890/). This manuscript showed that introducing each drug sequentially and switching once a threshold prevalence of resistance is reached had a shorter overall time to resistance to both drugs than introducing the drugs together (an "equal allocation" strategy). This is in keeping with the principle that diversifying the selective pressures from antibiotic use that drive antibiotic resistance results in a longer clinically useful lifespan for the drugs than rolling them out sequentially. In a new, just published paper (https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofag447/8737049?utm_source=authortollfreelink&utm_campaign=ofid&utm_medium=email&guestAccessKey=91ecb202-05ad-4098-9fca-35f2a7d331b7), we explored the impact of the initial epidemiological conditions at the time of drug rollout on optimal rollout strategy of the new drugs for gonorrhea. We found that rollout was most sensitive to the starting prevalence of resistance to the current treatment (ceftriaxone) and the frequency of screening for asymptomatic infections.